FY2022 Q3 Financial and R&D Update

ENHERTU® Gastric Cancer Update ENHERTU® was approved in the EU for patients with HER2+ unresectable advanced/recurrent gastric cancer in Dec 2022 Approval was based on the results from Ph2 study for 2nd line treatment in unresectable advanced/recurrent gastric cancer (DESTINY-Gastric02 in North America and Europe) and Ph2 study for 3rd line treatment (DESTINY-Gastric01 in Japan and Korea) DESTINY-Gastric02 data presented at ESMO 2022 ■ORR (Primary endpoint): 41.8% (95% CI: 30.8-53.4) ■DOR: 8.1 months (95% CI: 5.9-NE) ■ Safety profile was generally consistent with the established safety profile of ENHERTU® ■ Approval for the 2nd cancer type following breast cancer by EMA Daiichi-Sankyo CI: confidence interval, DoR: duration of response, EMA: European Medicines Agency, ESMO: European Society for Medical Oncology, NE: not estimable, ORR: objective response rate 21

View entire presentation